{"id":54267,"date":"2026-01-15T22:13:45","date_gmt":"2026-01-15T14:13:45","guid":{"rendered":"https:\/\/flcube.com\/?p=54267"},"modified":"2026-01-15T22:13:46","modified_gmt":"2026-01-15T14:13:46","slug":"wuxi-xdc-acquires-tot-bio-in-357m-deal-to-bolster-adc-cdmo-leadership","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54267","title":{"rendered":"WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership"},"content":{"rendered":"\n<p><strong>WuXi XDC<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2268:HKG\">HKG:\u202f2268<\/a>), a joint venture between <strong>WuXi Biologics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2269:HKG\">HKG:\u202f2269<\/a>) and <strong>WuXi STA<\/strong>, announced its acquisition of <strong>773\u202fmillion shares<\/strong> of <strong>TOT Biopharmaceutical International Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1875:HKG\">HKG: 1875<\/a>) at <strong>HKD\u202f4.00 (USD\u202f0.51) per share<\/strong>, representing a <strong>99\u202f% premium<\/strong> over the last undisturbed closing price of HKD\u202f2.01. The transaction values TOT Bio at up to <strong>HKD\u202f2.79\u202fbillion (USD\u202f357\u202fmillion)<\/strong> and will be funded from internal resources.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>WuXi XDC (HKEX:\u202f2268)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>TOT Biopharm (1875.HK)<\/td><\/tr><tr><td><strong>Shares Acquired<\/strong><\/td><td>773\u202fmillion shares<\/td><\/tr><tr><td><strong>Price per Share<\/strong><\/td><td>HKD\u202f4.00 (USD\u202f0.51)<\/td><\/tr><tr><td><strong>Premium<\/strong><\/td><td>99\u202f% over HKD\u202f2.01 closing price<\/td><\/tr><tr><td><strong>Total Consideration<\/strong><\/td><td>HKD\u202f2.79\u202fbillion (USD\u202f357\u202fmillion)<\/td><\/tr><tr><td><strong>Funding<\/strong><\/td><td>Internal resources<\/td><\/tr><tr><td><strong>Expected Close<\/strong><\/td><td>Q2\u202f2026 (subject to regulatory approvals)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TOT Bio Capabilities:<\/strong> Commercial\u2011scale manufacturing for <strong>ADCs and biologics<\/strong>, plus <strong>anti\u2011tumor drug R&amp;D, CDMO\/CMO services, and biologics out\u2011licensing<\/strong><\/li>\n\n\n\n<li><strong>Market Consolidation:<\/strong> Acquisition <strong>strengthens WuXi XDC\u2019s leading position<\/strong> in the <strong>ADC CDMO sector<\/strong>, adding validated production capacity and client base<\/li>\n\n\n\n<li><strong>Synergies:<\/strong> Integrates TOT Bio\u2019s <strong>end\u2011to\u2011end ADC capabilities<\/strong> with WuXi XDC\u2019s existing platform, creating a <strong>one\u2011stop shop<\/strong> from drug substance to finished product<\/li>\n\n\n\n<li><strong>Client Diversification:<\/strong> TOT Bio\u2019s <strong>out\u2011licensing pipeline<\/strong> provides WuXi XDC with <strong>upstream asset exposure<\/strong> and <strong>potential royalty streams<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-competitive-dynamics\">Market Impact &amp; Competitive Dynamics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Global ADC CDMO Market<\/strong><\/td><td>$8.5\u202fbillion<\/td><td>$12.3\u202fbillion<\/td><td>$17.8\u202fbillion<\/td><\/tr><tr><td><strong>WuXi XDC Market Share (pre\u2011deal)<\/strong><\/td><td>28\u202f%<\/td><td>31\u202f%<\/td><td>33\u202f%<\/td><\/tr><tr><td><strong>WuXi XDC Market Share (post\u2011deal)<\/strong><\/td><td>32\u202f%<\/td><td>36\u202f%<\/td><td>39\u202f%<\/td><\/tr><tr><td><strong>TOT Bio Revenue Contribution<\/strong><\/td><td>$85\u202fmillion<\/td><td>$120\u202fmillion<\/td><td>$155\u202fmillion<\/td><\/tr><tr><td><strong>Combined ADC Capacity<\/strong><\/td><td>+35\u202f% increase<\/td><td><\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Moat:<\/strong> WuXi XDC becomes the <strong>largest ADC CDMO globally<\/strong> by capacity and revenue, ahead of <strong>Lonza, Catalent, and Samsung Biologics<\/strong><\/li>\n\n\n\n<li><strong>Client Retention:<\/strong> TOT Bio\u2019s <strong>15+ ADC clients<\/strong> will be migrated to WuXi XDC\u2019s platform, reducing churn and expanding cross\u2011selling opportunities<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EPS Accretion:<\/strong> Transaction expected to be <strong>accretive to WuXi XDC\u2019s EPS<\/strong> by <strong>2027<\/strong>, driven by revenue synergies and cost rationalization<\/li>\n\n\n\n<li><strong>Debt Impact:<\/strong> All\u2011cash deal funded from <strong>$2.1\u202fbillion cash reserves<\/strong>; no external financing required<\/li>\n\n\n\n<li><strong>ROIC:<\/strong> Projected <strong>return on invested capital >15\u202f%<\/strong> by 2028<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding acquisition completion, market share projections, and revenue synergies. Actual results may differ due to regulatory approval timelines, integration challenges, and competitive responses.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011401581_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026011401581_c.\"><\/object><a id=\"wp-block-file--media-33166090-dc2a-475e-8d23-3179105ed6f9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011401581_c.pdf\">2026011401581_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011401581_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-33166090-dc2a-475e-8d23-3179105ed6f9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WuXi XDC (HKG:\u202f2268), a joint venture between WuXi Biologics (HKG:\u202f2269) and WuXi STA, announced its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,19,1183,952,2571,292,1998,364],"class_list":["post-54267","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-cro-cmo-cdmo","tag-hkg-2268","tag-hkg-2269","tag-tot-biopharm","tag-wuxi-biologics","tag-wuxi-sta","tag-wuxi-xdc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"WuXi XDC (HKG:\u202f2268), a joint venture between WuXi Biologics (HKG:\u202f2269) and WuXi STA, announced its acquisition of 773\u202fmillion shares of TOT Biopharmaceutical International Co., Ltd (HKG: 1875) at HKD\u202f4.00 (USD\u202f0.51) per share, representing a 99\u202f% premium over the last undisturbed closing price of HKD\u202f2.01. The transaction values TOT Bio at up to HKD\u202f2.79\u202fbillion (USD\u202f357\u202fmillion) and will be funded from internal resources.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54267\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership\" \/>\n<meta property=\"og:description\" content=\"WuXi XDC (HKG:\u202f2268), a joint venture between WuXi Biologics (HKG:\u202f2269) and WuXi STA, announced its acquisition of 773\u202fmillion shares of TOT Biopharmaceutical International Co., Ltd (HKG: 1875) at HKD\u202f4.00 (USD\u202f0.51) per share, representing a 99\u202f% premium over the last undisturbed closing price of HKD\u202f2.01. The transaction values TOT Bio at up to HKD\u202f2.79\u202fbillion (USD\u202f357\u202fmillion) and will be funded from internal resources.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54267\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T14:13:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-15T14:13:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54267#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54267\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership\",\"datePublished\":\"2026-01-15T14:13:45+00:00\",\"dateModified\":\"2026-01-15T14:13:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54267\"},\"wordCount\":372,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"CRO \\\/ CMO \\\/ CDMO\",\"HKG: 2268\",\"HKG: 2269\",\"Tot Biopharm\",\"WuXi Biologics\",\"WuXi STA\",\"WuXi XDC\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54267#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54267\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54267\",\"name\":\"WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-15T14:13:45+00:00\",\"dateModified\":\"2026-01-15T14:13:46+00:00\",\"description\":\"WuXi XDC (HKG:\u202f2268), a joint venture between WuXi Biologics (HKG:\u202f2269) and WuXi STA, announced its acquisition of 773\u202fmillion shares of TOT Biopharmaceutical International Co., Ltd (HKG: 1875) at HKD\u202f4.00 (USD\u202f0.51) per share, representing a 99\u202f% premium over the last undisturbed closing price of HKD\u202f2.01. The transaction values TOT Bio at up to HKD\u202f2.79\u202fbillion (USD\u202f357\u202fmillion) and will be funded from internal resources.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54267#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54267\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54267#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership - Insight, China&#039;s Pharmaceutical Industry","description":"WuXi XDC (HKG:\u202f2268), a joint venture between WuXi Biologics (HKG:\u202f2269) and WuXi STA, announced its acquisition of 773\u202fmillion shares of TOT Biopharmaceutical International Co., Ltd (HKG: 1875) at HKD\u202f4.00 (USD\u202f0.51) per share, representing a 99\u202f% premium over the last undisturbed closing price of HKD\u202f2.01. The transaction values TOT Bio at up to HKD\u202f2.79\u202fbillion (USD\u202f357\u202fmillion) and will be funded from internal resources.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54267","og_locale":"en_US","og_type":"article","og_title":"WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership","og_description":"WuXi XDC (HKG:\u202f2268), a joint venture between WuXi Biologics (HKG:\u202f2269) and WuXi STA, announced its acquisition of 773\u202fmillion shares of TOT Biopharmaceutical International Co., Ltd (HKG: 1875) at HKD\u202f4.00 (USD\u202f0.51) per share, representing a 99\u202f% premium over the last undisturbed closing price of HKD\u202f2.01. The transaction values TOT Bio at up to HKD\u202f2.79\u202fbillion (USD\u202f357\u202fmillion) and will be funded from internal resources.","og_url":"https:\/\/flcube.com\/?p=54267","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-15T14:13:45+00:00","article_modified_time":"2026-01-15T14:13:46+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54267#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54267"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership","datePublished":"2026-01-15T14:13:45+00:00","dateModified":"2026-01-15T14:13:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54267"},"wordCount":372,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","CRO \/ CMO \/ CDMO","HKG: 2268","HKG: 2269","Tot Biopharm","WuXi Biologics","WuXi STA","WuXi XDC"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54267#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54267","url":"https:\/\/flcube.com\/?p=54267","name":"WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-15T14:13:45+00:00","dateModified":"2026-01-15T14:13:46+00:00","description":"WuXi XDC (HKG:\u202f2268), a joint venture between WuXi Biologics (HKG:\u202f2269) and WuXi STA, announced its acquisition of 773\u202fmillion shares of TOT Biopharmaceutical International Co., Ltd (HKG: 1875) at HKD\u202f4.00 (USD\u202f0.51) per share, representing a 99\u202f% premium over the last undisturbed closing price of HKD\u202f2.01. The transaction values TOT Bio at up to HKD\u202f2.79\u202fbillion (USD\u202f357\u202fmillion) and will be funded from internal resources.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54267#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54267"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54267#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54267"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54267\/revisions"}],"predecessor-version":[{"id":54269,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54267\/revisions\/54269"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54267"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54267"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}